News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

QRxPharma Ltd. (QRXPY) Fails To Win Panel Backing For New Painkiller Moxduo


4/22/2014 5:11:26 PM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

QRxPharma Ltd. (QRX) failed to win the backing of U.S. regulatory advisers for its painkiller that combines two opioids in an attempt to reduce side effects.

The experimental drug Moxduo shouldn’t be approved and doesn’t provide enhanced safety compared with the opioids alone, a Food and Drug Administration advisory panel voted unanimously today. Moxduo combines morphine and oxycodone. If approved, the medicine would be the first combination pill with two opioids.

Help employers find you! Check out all the jobs and post your resume.

Read at Bloomberg
Read at New York Daily News
Read at NPR News
Read at Washington Post

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES